Obesity and atherogenic dyslipidemia

被引:122
|
作者
Bamba, Vaneeta
Rader, Daniel J.
机构
[1] Univ Penn, Sch Med, Med Ctr, Inst Diabet Obest & Metab, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Cardiovasc Inst, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA
[4] Childrens Hosp Philadelphia, Div Endocrinol, Philadelphia, PA 19104 USA
关键词
D O I
10.1053/j.gastro.2007.03.056
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Obesity is associated with an increased risk of coronary heart disease, in part due to its strong association with atherogenic dyslipidemia, characterized by high triglycerides and low high-density lipoprotein (HDL) cholesterol. There has been substantial research effort focused on the mechanisms of the link between obesity and atherogenic dyslipidemia, both in the absence and presence of insulin resistance. After a brief overview of the epidemiology of atherogenic dyslipidemia, this article details the known molecular mechanisms of adipocyte function and its relationship to apoB-containing lipoprotein assembly and metabolism, both in the healthy as well as in the obese states. We also discuss the pathophysiology of low HDL cholesterol in obesity and the implications for cardiovascular disease risk.
引用
收藏
页码:2181 / 2190
页数:10
相关论文
共 50 条
  • [41] Atherogenic dyslipidemia, underdiagnosed factor for cardiovascular complications
    Magdalena Aray-Andrade, Maria
    Elizabeth Lopez-Montanero, Edith
    Ariana Preciado-Gomez, Joselyne
    SALUD PUBLICA DE MEXICO, 2018, 60 (04): : 381 - 382
  • [42] Dyslipidemia and atherogenic risk in patients with rheumatoid arthritis
    Batun Garrido, Jose Antonio de Jesus
    Olan, Francisco
    Hernandez Nunez, Eufrates
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2016, 28 (03): : 123 - 131
  • [43] Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects
    Davidson, Michael H.
    Bays, Harold E.
    Stein, Evan
    Maki, Kevin C.
    Shalwitz, Robert A.
    Doyle, Ralph
    CLINICAL CARDIOLOGY, 2006, 29 (06) : 268 - 273
  • [44] SmartLab 2.0 in cardiovascular prevention of atherogenic dyslipidemia
    Toribio, Raquel Galvan
    Velilla, Teresa Arrobas
    Porillo, Cristobal Morales
    Rico, Miguel Angel
    Quesada, Mar Martinez
    Justel, Antonio Leon
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2023, 35 (03): : 123 - 128
  • [45] Nutritional recommendations in the prevention and treatment of atherogenic dyslipidemia
    Pascual, Vicente
    Luis Diaz, Jose
    Millan Nunez-Cortes, Jesus
    Perez-Martinez, Pablo
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2023, 35 (03): : 155 - 163
  • [46] Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk
    Vekic, Jelena
    Stromsnes, Kristine
    Mazzalai, Stefania
    Zeljkovic, Aleksandra
    Rizzo, Manfredi
    Gambini, Juan
    BIOMEDICINES, 2023, 11 (11)
  • [47] Beyond Cholesterol: The Atherogenic Consequences of Combined Dyslipidemia
    Kavey, Rae-Ellen W.
    Mietus-Snyder, Michele
    JOURNAL OF PEDIATRICS, 2012, 161 (06): : 977 - 979
  • [48] Search for genetic factors predisposing to atherogenic dyslipidemia
    Agustin G Yip
    Qianli Ma
    Marsha Wilcox
    Carolien I Panhuysen
    John Farrell
    Lindsay A Farrer
    Diego F Wyszynski
    BMC Genetics, 4
  • [49] Small LDL, atherogenic dyslipidemia, and the metabolic syndrome
    Grundy, SM
    CIRCULATION, 1997, 95 (01) : 1 - 4
  • [50] Atherogenic dyslipidemia: prevalence and management in lipid clinics
    Pedro-Botet, J.
    Flores-Le Roux, J. A.
    Mostaza, J. M.
    Pinto, X.
    de la Cruz, J. J.
    Banegas, J. R.
    REVISTA CLINICA ESPANOLA, 2014, 214 (09): : 491 - 498